An Open Label Phase I Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV
Phase of Trial: Phase I
Latest Information Update: 28 Jan 2015
Price : $35 *
At a glance
- Drugs Nintedanib (Primary) ; Carboplatin; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms VENUS-2
- 23 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Jun 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 17 Sep 2012 New trial record